(Q48310435)

English

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

0 references

0 references

bipolar I disorder

1 reference

based on heuristic

inferred from title

Raymond Sanchez

7

object named as

Raymond Sanchez

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

author name string

Ronald Marcus

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Arif Khan

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Linda Rollin

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Beth Morris

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Karen Timko

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

William Carson

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

publication date

1 March 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Bipolar Disorders

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

13

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

2

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

133-144

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Evidence-based guidelines for treating bipolar disorder: revised second edition--recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Prophylactic efficacy of lithium carbonate in manic-depressive illness. Report of the Veterans Administration and National Institute of Mental Health collaborative study group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Maintenance treatment for patients with bipolar I disorder: results from a north american study of quetiapine in combination with lithium or divalproex (trial 127).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126).

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

A rating scale for mania: reliability, validity and sensitivity

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

A New Depression Scale Designed to be Sensitive to Change

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

A rating scale for drug-induced akathisia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Improving the design of maintenance studies for bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Bipolar disorder and the metabolic syndrome: causal factors, psychiatric outcomes and economic burden

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Metabolic syndrome in outpatients receiving antipsychotic therapy in routine clinical practice: a cross-sectional assessment of a primary health care database

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2011.00898.X

21 January 2018

Identifiers

10.1111/J.1399-5618.2011.00898.X

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21443567

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48310435&oldid=2195031666"